Gilead Sciences Inc (GILD): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.2%. By the end of trading, Gilead fell $2.10 (-2.8%) to $72.42 on average volume. Throughout the day, 11,780,624 shares of Gilead exchanged hands as compared to its average daily volume of 8,586,100 shares. The stock ranged in price between $72.36-$74.06 after having opened the day at $73.92 as compared to the previous trading day's close of $74.52. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 39.4%, Echo Therapeutics ( ECTE), down 17.2%, PDL BioPharma ( PDLI), down 11.2% and Vision-Sciences Inc (DE ( VSCI), down 10.8%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $114.7 billion and is part of the drugs industry. The company has a P/E ratio of 41.1, above the S&P 500 P/E ratio of 17.7. Shares are up 102.9% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, OncoMed Pharmaceuticals ( OMED), up 97.9%, EnteroMedics ( ETRM), up 63.5%, Conatus Pharmaceuticals ( CNAT), up 18.1% and Unilife Corporation ( UNIS), up 16.6% , were all gainers within the health care sector with Tenet Healthcare ( THC) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition